BioPharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery
The November 2013 issue of BioPharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Genmab.
A liver divided Benjamin Boettner doi:10.1038/scibx.2014.302 Three independent teams have directly converted human fibroblasts to liver cells and eliminated a proliferation barrier from stem cell–based protocols. Full Text | PDF
Easy Access IP: ahead of the game or easy way out? C. Simone Fishburn doi:10.1038/scibx.2014.303 As university technology transfer offices grapple with how best to commercialize their discoveries, some are experimenting with different operating models that vary in the number and type of inventions they pursue for profit. Full Text | PDF
Translational tidbits Kai-Jye Lou doi:10.1038/scibx.2014.304 At least $440 million in new support for public-private partnerships was allocated last month globally. Almost $230 million of that amount is earmarked for the NIH's Accelerating Medicines Partnership. Full Text | PDF
Plasma lipids: harbingers of AD? Michael J. Haas doi:10.1038/scibx.2014.305 A team of U.S. researchers has shown that a panel of plasma lipid markers could predict Alzheimer's disease. The panel could enrich clinical trials testing disease-modifying therapies, but validation studies must first demonstrate the panel's specificity for AD over other forms of dementia. Full Text | PDF
Chemokine CXC motif ligand 10 (CXCL10; IP-10); CXC chemokine receptor 3 (CXCR3) doi:10.1038/scibx.2014.306 Human sample and mouse studies suggest inhibiting CXCR10 could help treat vitiligo. Full Text | PDF
IL-22; pim-1 (PIM1) doi:10.1038/scibx.2014.307 Mouse studies suggest inhibiting IL-22 or PIM1 could help treat psoriasis. Full Text | PDF
Spleen tyrosine kinase (SYK); FMS-like tyrosine kinase 3 (FLT3; CD135) doi:10.1038/scibx.2014.308 Cell-based and mouse studies suggest combined inhibition of SYK and FLT3 could help treat AML. Full Text | PDF
CpG island methylation; polycomb repressive complex 2 (PRC2); enhancer of zeste homolog 2 (EZH2) doi:10.1038/scibx.2014.309 Patient sample, cell culture and mouse studies suggest EZH2 inhibitors could help treat certain forms of ependymomas. Full Text | PDF
TANK-binding kinase 1 (TBK1); inhibitor of κ-light polypeptide gene enhanced in B cells kinase-ε (IKBKE; IKK-i); HER2 (EGFR2; ErbB2; neu) doi:10.1038/scibx.2014.310 In vitro and mouse studies suggest inhibiting TBK1 could help treat HER2+ breast cancers. Full Text | PDF
IL-33 (NF-HEV) doi:10.1038/scibx.2014.311 Mouse studies suggest IL-33 could be used as an adjuvant for cancer immunotherapy. Full Text | PDF
Notch 3 (NOTCH3); Musashi RNA binding protein 1 (MSI1) doi:10.1038/scibx.2014.312 In vitro and mouse studies suggest inhibiting NOTCH3 could help treat colon cancer. Full Text | PDF
TANK-binding kinase 1 (TBK1); inhibitor of κ-light polypeptide gene enhancer in B cells kinase-ε (IKBKE; IKK-i); Janus kinase-1 (JAK-1); JAK-2; K-Ras (KRAS) doi:10.1038/scibx.2014.313 Cell culture and mouse studies suggest inhibiting TBK1 could help treat lung cancers driven by KRAS mutations. Full Text | PDF
Squalene synthase (SQS; FDFT1); cyclooxygenase (COX) doi:10.1038/scibx.2014.314 In vitro and mouse studies suggest a new class of trifunctional, cholesterol-limiting, anti-inflammatory, antioxidant compounds could help treat atherosclerosis. Full Text | PDF
Not applicable doi:10.1038/scibx.2014.315 In vitro studies suggest a new class of synthetic polymers could help treat Candida albicans and other fungal infections. Full Text | PDF
IL-1 receptor doi:10.1038/scibx.2014.316 Mouse and human studies suggest IL-1 receptor antagonists could help prevent infections and treat colitis in patients with CGD. Full Text | PDF
p38 mitogen-activated protein kinase (p38 MAPK; MAPK14) doi:10.1038/scibx.2014.317 In vitro and mouse studies suggest partial inhibition of p38 MAPK signaling could help regenerate muscle in aged patients. Full Text | PDF
Solute carrier family 1 glial high affinity glutamate transporter member 2 (SLC1A2; EAAT2; GLT-1) doi:10.1038/scibx.2014.318 In vitro and mouse studies suggest EAAT2 translational activators could help treat neurological disorders including ALS and epilepsy. Full Text | PDF
Transient receptor potential cation channel subfamily C member 4 (TRPC4) doi:10.1038/scibx.2014.319 Mouse studies suggest inhibiting TRPC4 could help treat anxiety. Full Text | PDF
Phosphodiesterase-4 (PDE-4) doi:10.1038/scibx.2014.320 Rat and in silico studies suggest blocking PDE-4 inhibition could help treat kidney disease by sustaining podocyte differentiation. Full Text | PDF
CD28; CD244 natural killer cell receptor 2B4 (CD244; 2B4) doi:10.1038/scibx.2014.321 Mouse studies suggest selective CD28 blockade could help prevent transplant rejection. Full Text | PDF
Proteasome doi:10.1038/scibx.2014.322 In vitro studies identified belactosin A proteasome inhibitors with peptide boronate warheads that could help treat cancer or autoimmune diseases. Full Text | PDF
Plasma lipid signature to identify presymptomatic individuals that may progress to Alzheimer's disease (AD) doi:10.1038/scibx.2014.323 Clinical data suggest plasma lipids could help identify presymptomatic individuals who will develop AD or mild cognitive impairment (MCI). Full Text | PDF
Telomerase promoter activity–based assay to detect circulating tumor cells (CTCs) doi:10.1038/scibx.2014.324 An adenovirus that expresses GFP from the telomerase promoter could be used to detect CTCs in patients with brain cancer. Full Text | PDF
A hepatoma-based cell culture model that supports the entire cycle of HBV and HCV doi:10.1038/scibx.2014.325 Cell culture studies suggest a hepatoma-based cell culture model could aid the study of HBV and HCV infection and replication. Full Text | PDF
Bispecific, diagnostic antibodies for enhanced detection of dimerized or phosphorylated oncoproteins doi:10.1038/scibx.2014.326 Cell culture studies suggest bispecific antibodies specific for dimerized or phosphorylated proteins could be used in cancer diagnostics. Full Text | PDF
Induced multipotent progenitor cell–derived human hepatocytes (iMPC-Heps) with proliferative and functional potential in vivo doi:10.1038/scibx.2014.327 Cell culture and mouse studies suggest human iMPC-Heps could be used for disease modeling and could enable autologous liver therapy. Full Text | PDF
Müller glia cells as a source for regenerative retinal neuronal cell types doi:10.1038/scibx.2014.328 In vitro and mouse studies suggest Müller glia cells can be used to generate transplantable retinal progenitor cells for treating damaged or degenerating retinas. Full Text | PDF
Cerebrospinal fluid (CSF) levels of soluble CD19 to detect CNS disease in patients with lymphoma doi:10.1038/scibx.2014.329 Human sample studies suggest measuring soluble CD19 in CSF could be used to detect CNS disease in lymphoma patients and to aid prognosis and guide treatment. Full Text | PDF
Circulating giant macrophages as diagnostic markers for metastasizing tumors doi:10.1038/scibx.2014.330 Human sample studies suggest detection of circulating giant macrophages could be used to predict solid tumor metastasis. Full Text | PDF
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment